Bruker Corporation
Bruker Corporation (BRKR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
brkr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bruker Corporation (BRKR) measures how much investors pay for each dollar of the company's trailing earnings. BRKR's current PE ratio of N/A is calculated by dividing its stock price of $56.65 by its TTM earnings per share of -$0.08.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%40.1x
MedianQ3 · 75%77.2x
Max
At N/A, BRKR's current P/E is lower than in 0% of its annual fiscal year readings over the past 19 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bruker CorporationYou BRKR | $8.6B | N/A | — | -$0.08 |
 BrightSpring Health Services, Inc. Common Stock BTSG | $11.3B | 39.79x | +22.0% | $0.94 |
 Chemed Corporation CHE | $5.8B | 23.23x | -28.8% | $18.42 |
 CRISPR Therapeutics AG CRSP | $5.0B | N/A | — | -$6.47 |
 Glaukos Corporation GKOS | $7.2B | N/A | — | -$3.28 |
 iRhythm Technologies, Inc. IRTC | $3.6B | N/A | — | -$1.39 |
 Krystal Biotech, Inc. KRYS | $8.9B | 34.84x | +6.8% | $7.08 |
Industry Average 3 peers with valid PE | — | 32.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.06 | — | |
2024-12-31 FY2024 | 77.23x | $0.76 | +206.7% | |
2023-12-31 FY2023 | 25.18x | $2.92 | -26.5% | |
2022-12-31 FY2022 | 34.24x | $2.00 | -25.3% | |
2021-12-31 FY2021 | 45.85x | $1.83 | -12.9% | |
2020-12-31 FY2020 | 52.62x | $1.03 | +31.2% | |
2019-12-31 FY2019 | 40.11x | $1.27 | +55.0% | |
2018-12-31 FY2018 | 25.88x | $1.15 | -62.5% | |
2017-12-31 FY2017 | 69.03x | $0.50 | +210.2% | |
2016-12-31 FY2016 | 22.26x | $0.95 | -44.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bruker Corporation (BRKR) measures how much investors pay for each dollar of the company's trailing earnings. BRKR's current PE ratio of N/A is calculated by dividing its stock price of $56.65 by its TTM earnings per share of -$0.08.
Frequently asked questions
BRKR pe ratio · 6 questionsBRKR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $56.65 and TTM EPS of -$0.08. Data sourced from Financial Modeling Prep via BRKR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bruker Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08